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Abstract
The management of chronic medical conditions in a primary care practice requires
knowledge and commitment, particularly when providing services for the underserved. Type 2
diabetes mellitus (T2DM) is a complex and difficult condition that can result in complications
that affect multiple organ systems. Numerous studies have described GLP-1RAs and SGLT-2is
as complementary agents that can be used to prevent the multi-organ complications associated
with T2DM. The purpose of this Quality Improvement (QI) Project is to introduce combination
therapy with metformin and GLP-1RAs or SGLT-2is as part of an overall effort to address
hyperglycemia in patients with uncontrolled T2DM. The foundations of this QI practice include
a 10-day reflective practice in which T2DM was among the most frequent diagnoses. My
findings revealed that current therapeutic strategies used to manage T2DM were not fully
effective and might benefit from a change in practice. The implementation of this QI Project and
the adoption of effective therapy improve the future care of patients with uncontrolled T2DM,
their medication compliance, and their quality of life.
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Management of Uncontrolled Type 2 Diabetes Mellitus with Combination Therapy
with Metformin and/or Glucagon-like Peptide-1 Receptor Agonists/Sodium-Glucose
Cotransporter-2 Inhibitors
Background knowledge
Diabetes is a frequently-diagnosed chronic metabolic disorder that is associated with high
rates of morbidity and premature mortality. T2DM is currently a global healthcare priority.
While 360 million individuals were diagnosed with T2DM in 2011, this number is projected to
increase to 552 million by 2030 (Wei Sim et al., 2017). Uncontrolled T2DM leads to chronic
kidney disease, retinopathy, and neuropathy. The treatment for T2DM has evolved over the last
ten years and new drugs have become available that can be used to improve glycemic control and
reduce the incidence and progression of these complications. Glucagon-like peptide-1 receptor
agonists (GLP-1RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT-2is) are two types
of drugs that, in combination with metformin, are now considered first-line treatment for
uncontrolled T2DM. The mechanisms of action of these drugs complement each other and thus
are more effective at preventing hyperglycemia and its microvascular complications (Castellana
et al., 2019).
Numerous studies have described GLP-1RAs and SGLT-2is as complementary agents
that can be used to prevent the multi-organ complications associated with T2DM. The results of
these studies suggest that these drugs can be used as an early and more aggressive treatment of
T2DM in patients at low risk for developing hypoglycemia (Lajara, 2019). In their publication,
Simes and MacGregor (2019) review the recent guidelines for T2DM management, including the
recommendations provided by the American Diabetes Association. At this time, the first-line
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treatment for T2DM includes comprehensive lifestyle modifications together with metformin. If
there is no reduction in hemoglobin A1c (HbA1c) in response to first-line therapy,
guidelines suggest the addition of GLP-1RA or SGLT-2is to the metformin regimen to manage
uncontrolled T2DM and its complications.
The purpose of this Quality Improvement (QI) Project is to introduce combination
therapy with metformin and GLP-1RAs or SGLT-2is as part of an overall effort to address
hyperglycemia in patients with uncontrolled T2DM. The foundations of this QI practice include
a 10-day reflective practice in which T2DM was among the most frequent diagnoses. My
findings revealed that current therapeutic strategies used to manage T2DM were not fully
effective and might benefit from a change in practice. The implementation of this QI Project and
the adoption of effective therapy improve the future care of patients with uncontrolled T2DM.
Local problem
Uncontrolled T2DM is a common chronic medical condition in my primary care practice.
The local problem to be addressed by this QI Project is the implementation of effective
treatment. I realized the need for more effective therapy for patients with T2DM upon review of
my 10-day reflective practice log. Cardiovascular and renal complications are also common
among patients with uncontrolled T2DM. My review of the patient records revealed that
uncontrolled T2DM was not unique to my 10-day reflective practice These observations were
the critical factors leading to my decision to pursue a QI Project. The current medical literature
attests to the efficacy of GLP-1RAs and SGLT-2is at reducing HbA1c levels and the associated
cardiovascular and renal complications (Berkovic et al., 2020).
Intended improvement
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An advanced practice registered nurse (APRN) plays a critical role in providing care for
patients with T2DM. As an APRN working in a rural community in New Mexico, I need to
evaluate every patient before deciding on the most appropriate treatment. In addition to the
medical condition, I need to consider each patient’s medical insurance and socioeconomic status.
I recognize that every patient is a unique individual. Immigrants dominate this region, many of
whom are uninsured. Suboptimal insurance coverage increases the need for new, effective,
affordable, and cost-effective medical treatment for T2DM.
Frequent complications of T2DM include retinopathy, nephropathy, autonomic nerve
dysfunction, foot ulcers, and cardiovascular disease (Betonico et al., 2016). Hyperlipidemia is
frequently-identified as a comorbidity associated with T2DM that increases the risk of
developing peripheral vascular disease and stroke (Natali et al., 2021). In my practice, I need to
interpret the test results of each patient with T2DM and use this information to manage their
metabolic status. In addition, I need to evaluate the therapeutic options available for T2DM
treatment and their potential side effect.
This QI Project focuses on changing the current therapy of uncontrolled T2DM in my
practice. While current guidelines offer clinical decision support, policies also may need to be
updated. A report published by Bertoluci et al. (2020) provided updates of several guidelines and
clinical decision support systems currently used to manage T2DM. An evidence-based approach
recommends lifestyle modifications at all phases of treatment. First-line antidiabetic agents such
as metformin can be introduced to control HbA1c levels between 6.5–7.5%. Dual therapy is
recommended for patients presenting with higher HbA1c levels (7.5–9%); in the latter case,
metformin can be supplemented with an SGLT-2i or a GLP-1RA to provide glycemic control as
well cardiovascular and renal protection. Thus, metformin, SGLT-2is, and GLP-1RAs have
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become first-line agents for T2DM as they can provide effective glycemic control and
cardiovascular protection. The use of these first-line antidiabetic agents helps to control blood
glucose levels, reduce mortality associated with cardiovascular disease, and limit hospitalizations
for heart failure (Hernandez et al., 2018). Finally, if the HbA1c levels do not respond to either
monotherapy or dual therapy with first-line antidiabetic agents, the latest guidelines recommend
the use of three or as many as four agents.
Study question
My review of the 10-day reflective practice log highlighted the variety of chronic medical
conditions experienced by the patients in my rural primary care practice. I identified three
possible opportunities to improve the care provided to the patients. After meeting with my
chairperson, I selected diagnosis and management of uncontrolled T2DM as the subject of my QI
Project. T2DM has become highly prevalent among patients in my practice as well as in the
population at large.
Many factors influence the lack of compliance with medication regimens and
recommended lifestyle modifications. Consequently, many of the patients initially diagnosed
with T2DM will continue to exhibit elevated levels of HbA1c. In addition, many patients lack
the motivation to continue with recommended treatments when they do not attain the desired
outcomes, i.e., weight loss and decreased glucose levels. I have witnessed many complications of
T2DM in this patient population. The micro and macrovascular complications of uncontrolled
T2DM are frequently reflected in diagnoses that include hypertension, hyperlipidemia, chronic
kidney disease, and neuropathy (Simes & MacGregor, 2019). The development of these
complications largely reflects the quality and effectiveness of their treatment regimens. In my
practice, I was following the now-obsolete guidelines for T2DM management and added drugs to
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reduce HbA1c levels to standard levels without monitoring an individual patient’s increased risk
for complications. I realized that this practice was not sufficient and that my patients with T2DM
might benefit from more aggressive treatment. Therefore, once my chairperson approved my
PICOT (patient/population, intervention, comparison, outcome, time) question, I performed a
literature review and identified publications featuring the highest level of evidence to validate
my QI Project. My goal was to introduce high-level evidence-based therapy to improve the care I
currently provide for my patients. In the literature review for my QI Project interventions, I
identified publications that discussed the benefits, glycemic efficacy, safety, combination
efficacy, and tolerability of the first-line antidiabetic agents. Systematic reviews of randomized
controlled trials (RCTs) and meta-analyses revealed that GLP-1RAs and SGLT-2is either alone
or in combination therapy with metformin provide excellent glycemic control as well as
cardiovascular and renal protection.
Based on the review process, the PICOT question guiding the QI Project was as follows:
P: Patients 18–80 years of age who have been diagnosed with uncontrolled T2DM and managed
with metformin
I: Addition of a GLP-1RA and/or an SGLT-2i to metformin (i. e., combination therapy)
C: Monitor blood glucose via HbA1c levels
O: Reduction in HbA1c levels
T: Four weeks
Methods
Ethical issues
The PICOT question was generated upon review of a 10-day reflective practice from my
family practice clinic at La Clinica de Familia (LCDF) in rural Chapparal, New Mexico. I
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formulated the QI Proposal, including prescribing a GLP-1RA and/or an SGLT-2i to patients
currently managed with metformin who presented with uncontrolled T2DM. The QI Proposal
was submitted and accepted by my chairperson. The LCDF medical director, Dr. Gaston Berrios,
approved my project and signed the work letter that allowed me to complete my project at this
site. For ethical training in a QI intervention, I completed the Collaborative Institutional Training
Initiative (CITI) training before submitting the University of Texas at El Paso (UTEP)
Institutional Review Board (IRB) application. The UTEP IRB approved the QI Project on
November 17, 2021, and provided me with a letter designating it as not a research project. The
significance of this project involves efforts to initiate and monitor more effective treatment of
T2DM patients by implementing GLP-1RA/SGLT-2i combination therapy with metformin. The
goal of this project is to provide a more effective intervention that will control chronic
hyperglycemia in my T2DM patient population. I ensured patient confidentiality and anonymity
for the conduction of the QI Project.
Setting
Implementation of the QI Project took place at LCDF (Chaparral, New Mexico)
beginning on January 17, 2022, and concluding on February 18, 2022. Unfortunately, the
patients in my practice do not always have access to the most appropriate treatments. All
medications must be approved by the patient’s medical insurance carrier, and each insurance
company has its own drug formulary. Thus, the medication prescribed by the APRN may vary
based on insurance coverage. Similarly, medication selection for the uninsured depends on the
drug price. Fortunately, drug representatives frequently provide me with samples that I then
provide directly to the many uninsured patients with T2DM.
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Evidence-based research support that both GLP-1RAs and SGLT-2is are of benefit to
patients with T2DM whose condition remains uncontrolled on metformin alone. However, while
all three of these medications can be used to reduce glycemic levels, selection will depend
directly on the individual patient's cardiovascular and renal function (D'Marco et al., 2021).
Initiation of metformin is contraindicated for patients with a glomerular filtration rate (GFR)
below 45 mL/min; this drug should be discontinued immediately in patients with a GFR below
30 mL/min because of the risk of developing metabolic acidosis (Bertoluci et al., 2020).
SGLT-2is works by promoting glucose excretion in the urine and inhibiting glucose
reabsorption in the kidneys' proximal tubules, thereby enhancing glycosuria and reducing
glucose levels in the blood. By these actions, SGLT-2is limit the toxic effects of high serum
glucose levels on beta-cells (Zaccardi et al., 2016). A patient must present with a GFR >45
mL/min to meet the criteria for use of these drugs. Likewise, the starting dose of each drug varies
based on GFR. For example, empagliflozin (brand name, Jardiance®) can be initiated or
continued in patients with a GFR as low as 20 mL/min. By contrast, ertugliflozin (brand name,
Steglatro®) is not recommended for patients presenting with a GFR between 30 to <60 mL/min
and is contraindicated in patients with a GFR <30 mL/min. Some factors that restrict the efficacy
of these drugs include endogenous regulatory processes that limit hypoglycemia and caloric
intake while undergoing treatment with SGLT-2is (Zhou et al., 2020).
When used in combination with metformin, GLP-1RA provides complementary
hypoglycemic action, particularly after meals. GLP-1RAs mimic the actions of GLP-1, which is
an endogenous hormone produced in the small intestine in response to oral ingestion of glucose.
GLP-1RAs act at the GLP-1R to promote the secretion of incretin, which is a hormone that
promotes glucose-dependent insulin release by inhibiting glucagon secretion and promoting a
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sense of fullness associated with reduced intestinal motility (D'Marco et al., 2021). This
mechanism of action promotes reductions in HbA1c with additional benefits including weight
loss and the reduced risk of hypoglycemia. Administration of a GLP-1RA with metformin has
been proven to be safe and effective in patients with uncontrolled T2DM and typically results in
a marked reduction in HbA1c (Htike et al., 2017).
The main objective of therapy is to lower glycemic levels and prevent complications
associated with T2DM. Both GLP1-RA and SGLT-2is reduce HbA1c and provide cardiovascular
and renal protection via control of hyperlipidemia and blood pressure. Therefore, the purpose of
this QI Project is to apply evidence-based practice to reduce the glucose levels as reflected by
HbA1c in patients treated with metformin together with a GLP-1RA and/or an SGLT-2i.
Planning the intervention
The issue of uncontrolled T2DM and the selection of appropriate therapy has a
substantial impact on both health and quality of life. The implementation of this QI Project will
ensure that I am addressing the patient needs and will thus improve their satisfaction with my
care. My priority is to provide them with a meaningful contribution to their health. I am
obligated to safeguard patient health under my training and code of ethics. My efforts to reduce
glycemic levels in patients with uncontrolled T2DM may also prevent future complications.
In T2DM management, values measured include both fasting and postprandial glucose
levels as well as glycated hemoglobin in the form of HbA1c. Controlling glycemia includes an
assessment of acute serum glucose levels and HbA1c, the latter measured at least every three
months. Given the comparatively short timeframe for this intervention, I focused on more shortterm measurements provided by fructosamine tests. Fructosamine levels obtained every two
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weeks are currently the most inexpensive tests available for glucose monitoring (Selvin &
Mulder, 2022).
The implementation of this QI Project in the primary care setting includes patients who
meet the criteria who are for clinic visits during the four-week study period. Patients included are
female and male adults aged 18 to 80 years who are diagnosed with T2DM and undergoing
treatment with metformin. Each patient has scheduled a routine follow-up visit to evaluate
T2DM and blood laboratory results from a previous routine visit. I will include all patients
meeting these criteria, regardless of their insurance status. Patients with HbA1c levels between
7.5 – 9% were diagnosed with uncontrolled T2DM. Depending on their individual cardiovascular
and renal risk profiles, I provide the patient with information on GLP-1RAs and SGLT-2is and
prescribe the appropriate combination therapy. The following steps in the care process are
determined by a collaborative effort on the part of the patient and the provider.
Following the new guidelines (Li et al., 2020), one can consider adding either a GLP1RA or an SGLT-2is to metformin if the patient has no evidence of cardiovascular disease (CVD)
or chronic kidney disease (CKD). An SGLT-2i is prescribed for patients with heart failure or
CKD; if the patient is unable to tolerate this drug, a GLP1-RA can be substituted.
Contraindications for SGLT-2is include a GFR <45mL/min. Contraindications for GLP-1RA
include personal or family history of thyroid cancer (medullary thyroid cancer) or pancreatitis. If
uncontrolled T2DM persists in obese patients after three months of dual therapy, both SGLT-2is
and GLP-1Ras can be added to the initial metformin regimen. All patients are asked to selfrecord fasting and postprandial blood glucose levels after breakfast, lunch, dinner, and to bring
the logs to their follow-up appointment in two weeks. Baseline and two-week post-treatment
fructosamine levels are sufficient for an HbA1c calculation. Depending on the medical insurance

12
formulary or available samples, the specific medications prescribed are as follows: GLP-1RAs
including dulaglutide (name brand Trulicity®) or semaglutide (name brands Ozempic® and
Rybelsus®) and SGLT-2is including ertugliflozin (name brand Steglatro®) and empagliflozin
(name brand Jardiance®).
Planning the study of the intervention
The translational framework used in planning the study intervention and to provide
structure to this QI Project was Lewin's Change Model. This is a three-phase model (Unfreeze,
Change, and Refreeze) in which change results from a balance of both driving and restraining
forces (White et al., 2021). As a first step, I realized the need for a change in my practice and to
initiate more aggressive therapy for uncontrolled T2DM largely because of the growing number
of patients in my practice with this diagnosis and the limited improvement observed in responses
to the treatment provided (i. e., “Unfreeze”). The introduction of new medications to my practice
resulted in a disturbance to the status quo. However, the driving force toward change provided
me with the rationale needed to overcome resistance from existing barriers that would question
the clinical value of this new intervention. This initiative provided me with the impetus to plan
strategies to overcome problems, including the suboptimal medical insurance programs that
predominate in my patient population, and thus strengthen the reinforcement of change (i. e.,
“Change”). This step permitted me to prepare to introduce the QI intervention. The change phase
also includes real-world implementation of new therapeutic management strategies in my
practice that depend on laboratory results and medication tolerance of each patient, as well as
side effects, dose titration, and medication approval from insurance providers (i.e., “Refreeze”).
The refreeze phase will be facilitated by reduced glucose and HbA1c levels among the patients
enrolled in my QI Project. Furthermore, my evaluation of evidence-based practice outcomes for
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T2DM patients revealed the need to improve their therapeutic management in my practice. My
patients deserve to have access to optimal therapy that will prevent or reverse the complications
associated with T2DM. Sustainability of these new behaviors will allow the implementation of
these novel therapies as first-line treatment for uncontrolled T2DM in my practice.
I selected the Plan-Do-Study-Act (PDSA) as my QI Model. PDSA includes four cycles
for analysis of the intended change for each patient included in the QI project (Institute for
Healthcare Improvement [IHI], 2022). For my QI Project, the “Plan” phase involved the
generation of the evidence-based intervention. As part of the “Do” phase, I reviewed the plan of
treatment with the patients, including drug education and information on potential therapeutic
benefits and side effects, as well as their responsibility for maintaining daily records of blood
glucose levels, laboratory testing, and follow-up appointments. Real-world data are analyzed
during the “Study” phase, including a review of the glucose logs and fructosamine levels. During
this phase, the side effects of the new medication regimens are discussed and the next steps with
respect to treatment are determined. While the blood glucose and fructosamine data provide me
with information on the effectiveness of the new medication regimens, I also consider access to
therapy and its cost to the patient. This is followed by the “Act” phase which involves an
ongoing adjustment based on real-world evidence as the complete cycles bring opportunities to
identify other modifiable factors such as drug titration and/or issues with therapy adherence.
A review of the medical insurance formulary is critical to determine whether the patients
in my practice will have coverage for these medications. Although most of the patients in my
practice are covered by Medicaid of New Mexico in this rural community, some are covered by
Medicare and/or private insurance. As a provider, I researched the approved drug lists and
prepared a drug sample inventory before implementing the QI Project.
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Literature review
A Cochrane database search provided me with evidence-based literature to support the
proposed QI Project. A primary search resulted in nine articles that supported my selected
intervention. The secondary selection was somewhat more difficult due to the comparatively
large amount of evidence-based material available.
Several systematic reviews and meta-analyses of RCTs consider the efficacy and
tolerability of GLP-1RA and SGLT-2is. The overall conclusion is that use of these modalities in
combination with metformin has been proven to be effective.
Among these reports, Hussein et al. (2020) conducted a systematic review and network
meta-analysis on the efficacy and tolerability of SGLT-2Is and GLP-1RAs. The results of this
study revealed that long-acting GLP-1RAs provided superior outcomes with respect to
decreasing HbA1c, waist circumference, and body weight. By contrast, SGLT-2is were effective
at reducing blood pressure. The review also provided an evidence-based guide to the
management of T2DM. Among the adverse effects, GLP-1RAs have been associated with
gastrointestinal problems and SGLT-2is with genital infections.
Castellana et al. (2019) conducted a meta-analysis on the efficacy and safety of GLP1RAs as add-on therapy in cases in which SGLT-2is provided inadequate T2DM treatment. The
evaluation included four RCTs with a follow-up of at least 24 weeks and tracked reductions in
HbA1c to <7%. Weight loss and blood pressure control were also included in the outcome
measures. The results of this review support intensification with GLP-1RAs in patients whose
T2DM remains uncontrolled on SGLT-2is.
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Ding et al. (2020) compared the efficacy and safety of GLP-1RAs with SGLT-2is for
obese patients with uncontrolled T2DM that was managed with metformin. The study clearly
indicated that GLP-1RAs were superior to SGLT-2is in this patient population, albeit with
adverse effects including gastrointestinal events. Larger and longer-term follow-up clinical trials
will provide more evidence on the sustainable effects and safety of GLP-1RAs compared to
SGLT-2is.
RCTs focused on the safety and efficacy of a once-weekly dose of GLP-1RA together
with daily SGLT-2i compared to each regimen alone were compared in patients with T2DM that
was not adequately controlled with metformin. Jabbour et al. (2018) concluded that combination
therapy resulted in sustainable decreases in glycemia, systolic blood pressure, and weight over
52 weeks. No unanticipated safety findings were reported.
Zhou et al. (2019) published the results of a meta-analysis that focused on the efficacy
and safety of SGLT-2is and GLP-1RAs in combination versus SGLT-2is alone or with
metformin and concluded that combination therapy that included GLP-1RAs provided greater
benefits with respect to glycemic levels, weight, and systolic blood pressure control. However,
the authors did emphasize the need for individualized treatment while selecting monotherapy
versus a combination approach.
A systematic review and meta-analysis performed by Patoulias et al. (2019) also revealed
the improved antiglycemic efficacy of GLP-1RAs and SGLT-2is together compared to SGLT-2is
alone. In this study, reductions of HbA1c of 0.91% were observed (95% confidence interval [CI],
-141 to -0.42, I2 = 94%) with combination therapy compared to SGLT2is alone. The authors
suggest that combination therapy might provide important improvements in glycemic control and
promote weight reduction. However, the regimen is associated with a moderate risk of
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hypoglycemia and gastrointestinal side effects. Cardiovascular and renal outcomes are also
improved by this synergy.
Zaccardi et al. (2016) published the results of a systematic review and network metaanalysis that focused on the efficacy and safety of SGLT-2is in T2DM. The results revealed that,
although these agents increase the risk of contracting genital infections, the treatment is effective
for glycemic control and prevention of cardiovascular complications. The long-term outcomes of
these studies will need to be evaluated further.
Jia et al. (2020) performed a systematic review and meta-analysis focused on the use of
GLP-1RAs and SGLT-2is as monotherapy or add-ons to pre-existing metformin regimens. The
study outcomes revealed that GLP-1RAs have superior capacity to reduce HbA1c levels when
added to metformin compared to results from other incretin mimetics or SGLT-2is, and that
administration of SGLT-2is resulted in reductions in fasting plasma glucose both with or without
concomitant metformin therapy. The authors concluded that combination therapy with GLP1RAs or SGLT-2is resulted in reductions in HbA1c and fasting plasma glucose levels more
effectively when used as add-ons to metformin. Among their conclusions, the authors
recommended the use of GLP-IRAs or SGLT-2is as monotherapy to reduce the risk of
hypoglycemia and noted that all drugs should be selected on a patient-centered basis.
Mantsiou et al. (2020) published the results of another systematic review and metaanalysis in which GLP-1RAs and SGLT-2is were used as combination therapy for the treatment
of T2DM. Based on a review of four independent studies, the authors concluded that, compared
to monotherapy, combination therapy resulted in significant reductions in HbA1c levels with a
weighted mean difference of -0.61% (95% CI, -1.09% to -0.14%). While combination therapy
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resulted in no increased risk of hypoglycemia risk, there were only a few findings that addressed
cardiovascular outcomes and mortality.
I also reviewed several T2DM management guidelines, including those from the
American Diabetes Association, the American Society of Nephrology (Li et al., 2020), the
Portuguese-Brazilian evidence-based T2DM approach (Bertoluci et al., 2020), the clinical
decision support system from the department of biochemistry of the National University of
Singapore (Wei Sim et al., 2017) and results published by Hernandez et al. (2018). These
guidelines recommend the use of GLP1-RAs and/or SGLT-2is in combination with metformin
for patients with T2DM and atherosclerotic cardiovascular and renal complications. Berkovic et
al. (2020) studied the efficacy of combination therapy in a series of RCTs and identified the
benefits that might be realized in routine clinical practice and follow-up.
The results of the RCTs reviewed in these studies are reliable and provide high efficacy
and internal validity. The studies and meta-analyses focused on GLP-1RAs and SGLT-2is verify
that these RCTs were the results of well-conducted trials with rigorous methodology in
controlled clinical settings. The guidelines consider all data from the published RCTs and
provide results that can be used by medical providers as part of a highly structured approach for
clinical practice.
Methods of evaluation
HbA1c measurements are used widely as an indirect measure of mean blood glucose
levels and meet the United States Food and Drug Administration (FDA) requirements for
diabetes diagnosis and treatment efficacy. The results from the RCTs reviewed for this QI
Project measure treatment efficacy as reductions in HbA1c levels. This value reflects the average
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glucose exposure over a period of time as it measures the accumulated fraction of Hb that has
become glycosylated during the lifespan of a red blood cell (about 120 days). Other biomarkers
can be used to measure this parameter over a shorter timeframe. Fructosamine, which is a
measure of glucose linked to protein, is an excellent laboratory test for evaluating average
glucose exposure for this QI Project; it is inexpensive and provides an indirect measure of blood
glucose levels over the span of two to three weeks. Fructosamine levels ranging from 266 to 312
mmol/L are functionally equivalent to HbA1c levels of 7% (Selvin & Mulder, 2022). The
formula for HbA1c calculation ([0.017 x fructosamine level] + 1.61) converts fructosamine
levels in units of μmol/L to %HbA1c (Henderson et al., 2021). Each patient enrolled in the QI
Project has lab results with current HbA1c levels on file. In this project, I obtained a baseline
fructosamine level before initiating therapy and then again after two weeks for a short-term
evaluation of its impact on HbA1c levels. Each patient was also asked to provide a two-week
report of self-monitored of blood glucose levels (i.e., fasting, and post-prandial levels after
breakfast, lunch, and dinner). These data will provide supporting documentation for the
fructosamine levels measured after two weeks of treatment. I make certain that the patients have
fully understood the educational process via a demonstration of self-monitoring, blood glucose
recording, and fingerstick techniques. Documentation of blood glucose levels can be challenging
for many of my patients. The efforts and actions required to obtain medical insurance approval of
prescribed medications also present a significant barrier. To address this problem, I provide
initial drug samples and prepare proper authorization forms for approval using data from the
literature review for support. To ensure medical insurance coverage for the fructosamine levels,
the patient records are adjusted to include both the International Classification of Diseases (ICD)
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10 Code Z51.81, Encounter for therapeutic drug level monitoring as well as the primary ICD 10
Code E11.65, Diagnosis of T2DM with hyperglycemia.
Analysis
Implementation of this QI Project began on January 17, 2022. Ten patients with T2Dm
were seen during the ensuing four weeks. The Study phase of the PDSA QI Model was used to
direct this analysis. Baseline HbA1c values were measured before each of these appointments as
part of the laboratory tests that were ordered after the previous follow-up visit. A baseline
fructosamine level was obtained on the day of the appointment; a second fructosamine level was
obtained at the two-week follow-up visit scheduled after the intervention. I analyzed the
fructosamine results using the traditional parametric conversion method which permitted me to
assess changes in HbA1c over the first two weeks on the new drug regimen. The next scheduled
HbA1c measurement will be performed three months after implementation of the QI Project.
My analysis of the laboratory results determines the next step of treatment. As shown,
fructosamine levels and thus calculated HbA1c decreased consistently in all patients. The plan
was adopted based on these positive results.
Results
Outcomes
Patient 1 was a 56-year-old male who was first seen in my clinic on January 17, 2022. He
has been taking metformin 1000 mg twice a day. Based on his laboratory results that included an
HbA1c level of 10.2%, the patient was prescribed dulaglutide (Trulicity®) at a dose of 0.75
mg/0.5 mL once a week and empagliflozin (Jardiance®), one 10 mg tablet once a day. The first
dose of dulaglutide was provided on the day of the clinic visit. A fructosamine level of 378
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μmol/L was measured at this visit. The patient presented at his two-week follow-up visit on
January 31, 2022. A second fructosamine level measured at this time was 318 μmol/L (calculated
HbA1c 7.06 %). The patient reported that he was following a healthier diet since the initiation of
the treatment although he noted occasional feelings of low energy. At a four-week follow-up
appointment on February 14, 2022, the dulaglutide dose was kept in 0.75 mg/0.5 mL and the
empagliflozin remained in 10 mg because of two episodes of hypoglycemia. Will follow up in
three months for HbA1c. His medical insurance was Blue Cross Blue Shield (BCBS) Centennial
(Medicaid of New Mexico) that required a prior authorization. I wrote a letter including data
from my literature review and obtained approval for both drugs. Final result: outcomes met (see
Figures 1 and 3).
Patient 2 was a 61-year-old female who was first seen in my clinic on January 17, 2022.
She was taking metformin 1000 mg twice a day. Based on her laboratory results, including an
HbA1c level of 10.7%, the patient was prescribed dulaglutide (Trulicity®) at a dose of 0.75
mg/0.5 mL once a week. She received the first dose of this medication on the same day as the
clinic visit. She was not a candidate for an SGLT-2i because her GFR was <30 mL/hr. Her first
fructosamine level was 437 μmol/L; the second fructosamine level measured at her two-week
follow-up visit was 360 μmol/L (calculated HbA1c 7.73 %) . The patient reported that she had
experienced no side effects. At her four-week follow-up visit (February 14, 2022), her
dulaglutide dose was increased to 1.5 mg/0.5 mL. Will follow up in three months for HbA1c.
Her medical insurance was Presbytrerian Centennial (Medicaid of New Mexico) that required a
prior authorization. I wrote a letter including data from my literature review and obtained
approval. Final result: outcomes met (see Figures 1 and 3).
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Patient 3 was a 55-year-old female who was first seen in my clinical on January 18, 2022;
Her HbA1c level at that time was 10.4%. She was taking metformin 1000 mg twice a day. She
has a history of CVD; she had undergone a coronary artery bypass graft procedure and remains
at ongoing risk for developing renal disease. Her lipid levels were mildly elevated and were
treated with statin drugs. Her baseline fructosamine level was 410 μmol/L. She was prescribed
dulaglutide (Trulicity®) 0.75 mg/0.5 mL once a week and ertugliflozin (Steglatro®) 15 mg once
a day. She received the first dose of dulaglutide at the clinic. Her two-week follow-up
fructosamine level on February 2, 2022, was 325 μmol/L (calculated HbA1c 6.115 %). The
patient reports no side effects from these medications. She reports that this is reducing her
carbohydrate intake, including the elimination of sugar-sweetened sodas. At the four-week
follow-up appointment (February 15, 2022) she again reported no side effects. Her dulaglutide
dose was increased to 1.5 mg/0.5 Ml and kept ertugliflozin at 15 mg (highest dose). Will follow
up in three months for HbA1c. Her medical insurance was BCBS Centennial (Medicaid of New
Mexico) that required a prior authorization. I wrote a letter including data from my literature
review and obtained approval for both drugs. Final result: outcomes met (see Figures 1 and 3).
Patient 4 was a 57-year-old male who was first seen in my clinic on January 18, 2022.
His HbA1c level at that time was 7.9%. He was taking metformin 1000 mg twice a day. His first
fructosamine level was 279 μmol/L. He was prescribed ertugliflozin (Steglatro®) 5 mg tablets
once a day. At his two-week follow-up visit (February 2, 2022) his fructosamine level was 265
μmol/L (calculated HbA1c 6.115 %). No side effects were reported. He will continue on this
dose of ertugliflozin (5 mg/day) and will follow up in three months for HbA1c. BCBS
Centennial was his insurance (Medicaid of New Mexico) that required a prior authorization. I
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wrote a letter including data from my literature review and obtained approval. Final result:
outcomes met (see Figures 1 and 3).
Patient 5 was a 49-year-old female who was first seen in my clinic on January 19, 2022.
Her HbA1c level at that time was 7.9%. She was taking metformin 1000 mg twice a day. Her
first fructosamine level was 278 μmol/L. She was prescribed ertugliflozin (Steglatro®) 5 mg
tablets once a day. His fructosamine levels decreased to 247 μmol/L (calculated HbA1c 5.8 %) at
the two-week (February 4, 2022). She will continue on this dose of ertugliflozin (5 mg/day) and
will follow up in three months for HbA1c. The patient is uninsured, will provide her ertugliflozin
5 mg monthly. Final result: outcomes met (see Figures 1 and 3).
Patient 6 was a 53-year-old male who was first seen on January 19, 2022, with an HbA1c
level of 9.9%. He was taking metformin 1000 mg twice a day. His first fructosamine level was
417 μmol/L. He was prescribed semaglutide (Ozempic®) at a dose of 0.25 mg once a week. His
fructosamine level at his two-week follow-up (March 2, 2022) was 335 μmol/L (calculated
HbA1c 7.3 %). At his four-week follow-up visit on February 16, 2022, he reported no side
effects, and the dose of semaglutide was increased to 0.5 mg once a week. Will follow up in
three months for HbA1c. The patient is uninsured, will provide semaglutide one box once a
month. Final result: outcomes met (see Figures 2 and 4).
Patient 7 was a 57-year-old male who was first seen on January 19, 2022, and presented
with an HbA1c level of 9.5%. He was taking metformin 1000 mg twice a day. His fructosamine
level at that time was 369 μmol/L. He was prescribed dulaglutide (Trulicity®) at a dose of 0.75
mg/0.5 mL once a week and provided with the first dose on that same day. At his two-week
follow-up visit on February 2, 2022, his fructosamine level was 350 μmol/L (calculated HbA1c
7.56 %). He reported no lifestyle modifications. He reported one episode of nausea as a side
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effect of the new medication. At the four-week follow-up on February 16, 2022, the dose of
dulaglutide was increased to 1.5 mg/0.5 mL. He was instructed to report any side effects. He
reported frequent nausea and the dose was adjusted back to 0.75 mg/0.5 mL. I recommended him
lifestyle modifications reducing carbohydrate intake and increasing his physical activity. Will
follow up in three months for HbA1c. BCBS Centennial was his insurance (Medicaid of New
Mexico) that required a prior authorization. I wrote a letter including data from my literature
review and obtained approval. Final result: outcomes met (see Figures 2 and 4).
Patient 8 was a 50-year-old female who was seen in my clinic on January 20, 2022, with
an HbA1c level of 10%. She was taking metformin 1000 mg twice a day. Her fructosamine level
at that time was 364 μmol/L. She was prescribed dulaglutide (Trulicity®) at a dose of 0.75
mg/0.5 mL once a week. At her two-week follow-up visit (February 3, 2022) her fructosamine
level was 335 μmol/L (calculated HbA1c 7.31 %). She reported intermittent episodes of low
fasting blood glucose levels. I increased the dose of dulaglutide to 1.5 mg/0.5 mL on February
17, 2022, at her four-week follow-up visit. Given her reports of episodes of hypoglycemia, an
SGLT-2i was not added to her medication regimen. Will follow up in three months for HbA1c.
Presbyterian Centennial was her insurance (Medicaid of New Mexico) that required a prior
authorization. I wrote a letter including data from my literature review and obtained approval.
Final result: outcomes met (see Figures 2 and 4).
Patient 9 was a 77-year-old male who was seen in my clinic on January 21, 2022, with an
HbA1c level of 8.2%. He was taking metformin 1000 mg twice a day. His first fructosamine
level was 281 μmol/L and dulaglutide (Trulicity®) was initiated at a dose of 0.75 mg/0.5 mL
once a week. At the two-week follow-up visit (February 4, 2022), his fructosamine level was 264
μmol/L (calculated HbA1c 6.1 %). He reported no side effects and the dulaglutide dose was kept
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on 0.75 mg/0.5 mL. Will follow up in three months for HbA1c. Medicare was his medical
insurance and covered the drug once it was prescribed. Final result: outcomes met (see Figures 2
and 4).
Patient 10 was a 46-year-old female who was seen in my clinic on February 1, 2022, with
an HbA1c level of 10.4%. She was taking metformin 1000 mg twice a day. She was prescribed
semaglutide (Ozempic®) at a dose of 0.25 mg once a week. The first dose was provided to her at
the clinic. Her first fructosamine level was 358 μmol/L. Her fructosamine level at her two-week
follow-up visit (February 15, 2022) was 338 μmol/L (calculated HbA1c 7.4 %). She reported no
side effects and her dose was increased to 0.5mg at the four-week follow-up on March 1, 2022.
Will follow up in three months for HbA1c. The patient is uninsured, semaglutide will be
provided one box every month. Final result: outcomes met (see Figures 2 and 4).
Changes in fructosamine levels detected in each patient are shown in Figures 1 and 2.
The calculated HbA1c values are shown in Figures 3 and 4.
Figure 1
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Figure 2
Fructosamine Levels Before and After Implementation in Patients 6–10
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Figure 3
HbA1c Calculated from Fructosamine Levels Before and After Implementation in Patients 1–5
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Figure 4
HbA1c Calculated from Fructosamine Levels Before and After Implementation in Patients 6–10
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Discussion
Summary
With the development of new drugs, guidelines and recommendations for the
management of uncontrolled T2DM have changed. The effectiveness, efficacy, and tolerability
of the GLP-1RAs and SGLT-2is have been tested and proven repeatedly as indicated by the
results of my literature review. The results of the implementation of this QI Project affirms that
both GLP-1RA and SGLT-2i together with metformin are useful and effective and may be
adopted as the first line of therapy for the management of uncontrolled T2DM. The outcome of
the QI Project reveals the effectiveness of the therapy.
The patients accepted the new therapy and many were committed to pursuing lifestyle
modifications. All patients exhibited reduced HbA1c levels as determined from serial
fructosamine levels. The act of recording blood glucose levels also serves as motivation for
continued adherence to this new therapy.
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Only one of the ten patients enrolled in this project received medication coverage at the
time that it was prescribed. Continuation of therapy after the initial implementation is of course
vital. In addition to the reduction in glycemic levels, I was also successful in obtaining prior
authorization for the prescribed medications as part of the implementation of this project. The
differences in fructosamine levels observed over a period of two weeks provided substantial
motivation for my patients, many of whom were excited to see these results. While patient
compliance with blood glucose recording remains a challenge, many became more motivated to
do so after seeing the initial positive results and realizing the effectiveness of the therapy.
Among the strengths of this study, the therapeutic regimens prescribed resulted in a
reduction in glycemic levels that could be appreciated at the two-week follow-up visit. The
possibility of weight loss is another plus to this study, as noted by one patient at the four-week
follow-up visit. Another strength of the strategy used here is the availability of sample drugs that
can be provided to the patients at the first appointment. Likewise, information that I provided
from my literature review virtually guaranteed pre-authorization approval by the various medical
insurance providers.
Relation to other evidence
As part of this project, I identified studies on combination therapy and reviews of RCTs,
and meta-analyses that all emphasized glycemic control. The impact of uncontrolled T2DM on
the cardiovascular and renal systems and the role of effective intervention therapy was a
common denominator of every study in the literature review. The studies discussed in the
following paragraphs consider different approaches the therapy implementation.
Nelson et al. (2021) reviewed the cardiovascular outcomes associated with glycemic
control. The data for this study were obtained from positive trials reported since 2015 in which
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glucose-lowering therapy with SGLT-2is and GLP-1RAs resulted in the prevention of
cardiovascular events. These authors note that primary care providers such as APRNs share
responsibility with cardiologists and encourage them to include both drugs in the treatment of
diabetic patients at risk for developing CVD.
Ding et al. (2020) published a systematic review and meta-analyses of RCTs to compare
the efficacy and safety of GLP-1RAs and SGLT-2is for the treatment of uncontrolled T2DM in
obese patients who were undergoing treatment with metformin. The results of this overview
suggest that GLP-1RAs are superior to SGLT-2is in providing glycemic control specifically in
obese patients. The side effects mentioned included gastrointestinal events only. Larger and
longer-term follow-up clinical trials will be needed to provide more evidence in support of the
safety and efficacy of GLP1-RAs compared to SGLT-2is.
A consensus statement by the European Renal and Cardiovascular Medicine (EURECAm) and Diabetes and Obesity (DIABESITY) working groups of the European Renal Association
and the European Dialysis and Transplant Association noted that the use of GLP-1RAs and
SGLT-2is to reduce glycemia in patients with T2DM was associated with significant
cardiovascular and renal benefits. The consensus was based on observations that both of these
drugs promote effective control of glycemia, ameliorate progressive failure of pancreatic betacells, and limit weight gain; these benefits were introduced as “the unmet needs of
nephroprotection and cardioprotection in diabetic kidney disease.” RCTs were used to prove
their superiority to standard treatment in FDA filings (Sarafidis et al., 2019).
Limitations
The time frame (four weeks) was one of the main limitations of this QI Project. Similarly,
the study included only a small group of patients, and the available therapies were limited to
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drugs covered in the formularies provided by their medical insurance. While the initial follow-up
for this QI Project was two weeks, some side effects first presented themselves at week three and
four of therapy. Specific dose adjustments were made to three patients at that time. Thus, future
patient outcomes may be somewhat more limited as side effects could have an impact on
medication compliance. Other limitations include the fact that frequent laboratory tests are not
usually covered by medical insurance. I found that I needed to include another ICD code in
addition to the primary designation (uncontrolled T2DM) to obtain approval for fructosamine
levels both at baseline and at two weeks; otherwise, the patient would be charged for this test.
Finally, I was able to carry out this project because of the availability of samples from drug
representatives; this variable is another limitation placed on those caring for the uninsured.
Interpretation
APRNs with DNP degrees are trained to analyze and interpret the needs for changes in
their current practice. In this project, I identified critical evidence-based approaches aimed at
improving drug therapy and attaining the desired patient outcomes. Combination therapy with
metformin and/or a GLP-1RA or an SGLT-2i assures effective treatment. APRNs should
consider adapting this QI Project intervention for the management of their patients who present
with uncontrolled T2DM. This QI Project contributes to a high quality of care and the
achievement of desired patient outcomes.
Conclusions
Uncontrolled T2DM and its complications are major public health problems.
Observations linking persistent hyperglycemia to the progression of cardiovascular and renal
disease have been among the reasons promoting significant changes in the current guidelines for
diabetes management. The results of many reviews of RCTs and network meta-analyses have

30
documented the efficacy and safety of GLP-1RAs and/or SGL-2is in combination with
metformin as a means to provide glycemic control and protection against cardiovascular and
renal disease. The implementation of this DNP QI Project brought effective therapy to my
practice. Project participants experienced reduced glycemic levels in only two weeks. As a leader
and a doctorate-prepared nurse, my impact is perceived in my attention to patient care and the
outcomes that result. My ongoing efforts will serve to improve my primary care therapy
controlling T2DM.
Other information
Funding
Funds for this QI Project were provided by the Paso del Norte Health Foundation
Graduate Fellows Program for Academic Excellence and Leadership.
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